CIPAN

Cipan increases investment in Vila Franca de Xira with a new antibiotic

Cipan – Companhia Industrial Productora de Antibioticos will exclusively supply the raw material for a new antibiotic that will be launched, in the first quarter of 2019, in the United States. Approved in October by the US authorities, “Nuzyra” is based on omadicicline, which will be produced in the Portuguese industry installed 55 years ago in the Carregado Vala, north of the municipality of Vila Franca de Xira.

To develop this production, Cipan will invest about six million euros in its own unit, a figure that joins the eight million already invested in the factory in the last two years by the Spanish group SUANFARMA, which acquired Cipan in 2016. The Portuguese company, specialized in the manufacture and marketing of active pharmaceutical ingredients, mainly antibiotics, but also other raw materials, is undergoing a growth phase. In 2017 it had a turnover of 19.2 million euros, 7.6 million more than the previous year. And it plans to reach 25 million by 2018.

Héctor Ara, president of the SUANFARMA group, makes a positive assessment  on the acquisition of the Portuguese company, stressing that it has accumulated know-how and is one of the few in the world that has the conditions to produce, simultaneously, pharmaceutical compounds by fermentation and by chemical synthesis. Héctor Aras told PÚBLICO that it is SUANFARMA’s intention to transfer its research center, currently in Barcelona, ​​to Cipan’s facilities.

Read more in source: Publico

Read More
LOGOCIPAN

Corporate Event Notice

Delisting of shares

As of 28/09/2018, ordinary shares (ISIN PTCPN0AE0002) issued by CIPAN-IND.PRODUTOS ANTIBIOTIC.
will be delisted from EURONEXT ACCESS LISBON.

Reason: Decision of Euronext based on rule 5.2., 5 of Euronext Access Rule Book
Delisting date: 28/09/2018
Last trading date: 27/09/2018
Euronext Designation: CIPAN
ISIN code: PTCPN0AE0002 Euronext code: PTCPN0AE0002
Trading Symbol: CPN National code: CPN AE

The present notice and the contents thereof are only provided for information purposes in order to facilitate the fair, orderly and efficient functioning of the market and is not a recommendation to engage in investment activities. The contents of this notice are provided “as is” based on information provided to the market operator without representation or warranty of any kind. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this notice shall form the basis of any contract. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator.

Read More